377 related articles for article (PubMed ID: 2108851)
21. A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators.
O'Connor CM; Meese RB; McNulty S; Lucas KD; Carney RJ; LeBoeuf RM; Maddox W; Bethea CF; Shadoff N; Trahey TF; Heinsimer JA; Burks JM; O'Donnell G; Krucoff MW; Califf RM
Am J Cardiol; 1996 Apr; 77(10):791-7. PubMed ID: 8623729
[TBL] [Abstract][Full Text] [Related]
22. Thrombolytic therapy in Europe: current status.
Vahanian A
Eur Heart J; 1996 Sep; 17 Suppl E():21-7. PubMed ID: 11824000
[TBL] [Abstract][Full Text] [Related]
23. Thrombolytic agents for acute evolving myocardial infarction: comparative effects.
Sherry S
Ration Drug Ther; 1987 Jan; 21(1):1-9. PubMed ID: 3112866
[No Abstract] [Full Text] [Related]
24. Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute myocardial infarction. Preliminary results of a randomised study.
Monnier P; Sigwart U; Vincent A; Bachmann F; Goy JJ; Schaller MD; Kaufmann U; Badan M; Grbic M; Perret C
Drugs; 1987; 33 Suppl 3():175-8. PubMed ID: 3315587
[TBL] [Abstract][Full Text] [Related]
25. Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction.
Sherry S
Am J Med; 1987 Aug; 83(2A):31-46. PubMed ID: 3115099
[TBL] [Abstract][Full Text] [Related]
26. [Fibrinolytic agents--who benefits when?].
Weichert W; Seifried E
Ther Umsch; 1995 Oct; 52(10):652-60. PubMed ID: 7482376
[TBL] [Abstract][Full Text] [Related]
27. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.
Chesebro JH; Knatterud G; Roberts R; Borer J; Cohen LS; Dalen J; Dodge HT; Francis CK; Hillis D; Ludbrook P
Circulation; 1987 Jul; 76(1):142-54. PubMed ID: 3109764
[TBL] [Abstract][Full Text] [Related]
28. Current issues concerning thrombolytic therapy for acute myocardial infarction.
Hennekens CH; O'Donnell CJ; Ridker PM; Marder VJ
J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):18S-22S. PubMed ID: 7775709
[TBL] [Abstract][Full Text] [Related]
29. Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.
Monk JP; Heel RC
Drugs; 1987 Jul; 34(1):25-49. PubMed ID: 3308411
[TBL] [Abstract][Full Text] [Related]
30. Achievement of coronary artery patency by use of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Hillis WS; Hornung RS; Hogg KJ; Hockings N; Burns JM; Dunn FG
Drugs; 1987; 33 Suppl 3():117-23. PubMed ID: 3315576
[TBL] [Abstract][Full Text] [Related]
31. Safe use of thrombolysis in the elderly.
Wittry MD; Thornton TA; Chaitman BR
Geriatrics; 1989 Nov; 44(11):28-30, 33-6. PubMed ID: 2509296
[TBL] [Abstract][Full Text] [Related]
32. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.
Anderson JL
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):22B-27B. PubMed ID: 3312369
[TBL] [Abstract][Full Text] [Related]
33. The effect of thrombolytic therapy with anisoylated plasminogen streptokinase activator complex on the indicators of myocardial salvage.
Buchalter MB; Bourke JP; Jennings K; Adams PC; Kenmure AC; Hah CW; Reid DS
Drugs; 1987; 33 Suppl 3():209-15. PubMed ID: 3315593
[TBL] [Abstract][Full Text] [Related]
34. Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study.
Bassand JP; Cassagnes J; Machecourt J; Lusson JR; Anguenot T; Wolf JE; Maublant J; Bertrand B; Schiele F
Circulation; 1991 Sep; 84(3):1107-17. PubMed ID: 1909218
[TBL] [Abstract][Full Text] [Related]
35. Reperfusion, patency and reocclusion with anistreplase (APSAC) in acute myocardial infarction.
Anderson JL
Am J Cardiol; 1989 Jul; 64(2):12A-17A; discussion 24A-26A. PubMed ID: 2662737
[TBL] [Abstract][Full Text] [Related]
36. New thrombolytic drugs in acute myocardial infarction: theoretical and practical considerations.
Verstraete M
Circulation; 1987 Aug; 76(2 Pt 2):II31-8. PubMed ID: 3111745
[No Abstract] [Full Text] [Related]
37. Thrombolytic, antiplatelet, and antithrombotic agents.
Grines CL
Am J Cardiol; 1992 Dec; 70(21):18I-26I. PubMed ID: 1471601
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of 2 intravenous thrombolytic agents (anisoylated plasminogen streptokinase activator complex versus streptokinase) in patients with acute myocardial infarction.
Seabra-Gomes R; Aniceto Silva J; Aleixo A; Real T; Freire I; Torres I; Freitas R; Crespo F
Drugs; 1987; 33 Suppl 3():169-74. PubMed ID: 3315586
[TBL] [Abstract][Full Text] [Related]
39. Designing thrombolytic agents: focus on safety and efficacy.
Collen D
Am J Cardiol; 1992 Jan; 69(2):71A-81A. PubMed ID: 1729881
[TBL] [Abstract][Full Text] [Related]
40. Improved left ventricular function in myocardial infarction following intravenous thrombolytic therapy with acylated plasminogen activator.
Ovsyshcher I; Silber H; Hausman MI; Margolis G; Gueron M
Angiology; 1990 Feb; 41(2):133-8. PubMed ID: 2407157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
